Australia’s Prana Misses Primary Endpoint In POC Alzheimer’s Disease Trial; Stock Tanks
This article was originally published in PharmAsia News
Prana’s lead Alzheimer’s candidate fails both primary and secondary endpoints in Alzheimer’s proof-of-concept- trial, but the company still has hopes that an extension study will show a stronger signal.
You may also be interested in...
Australia's Prana Charging Into Confirmatory Trials For Alzheimer's Drug That Looks To Alter Disease
PERTH, Australia - Melbourne-headquartered biotech Prana is gearing up to begin confirmatory trials for its lead molecule PBT2, an Alzheimer's disease treatment that has demonstrated surprising ability to reverse dementia symptoms
Prana’s COO Diane Angus, Head Of Research Robert Cherny On Prana’s Unique Mechanism Of Action In Neurodegenerative Drug Development: An Interview With PharmAsia News (Part 2 of 2)
Established in 1997, Melbourne, Australia-based biotech company Prana has developed a library of chemical compounds that addresses the role of biological metals in human disease. The company's lead compound PB2 in Alzheimer's disease completed Phase IIa clinical trials, and the company recently announced a preclinical candidate for Parkinson's disease. "Prana" is Sanskrit for "moving force," or "life force," which sustains life and diminishes as humans age. The company has formed its business strategy on neurological disorders that result from interactions between selected metals and target proteins as the brain ages. COO Diane Angus and Head of Research Robert Cherny sat down with PharmAsia News in Australia to talk about Prana's unique approach to developing compounds in the neurodegenerative space.
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.